MENU
XBI
AS OF
Nov 25 closing price
Price
$121.37
Change
+$1.79 (+1.50%)
Net Assets
7.52B
Intraday BUY SELL Signals
OUR PRODUCTS
MOBILE APPS
GENERAL INFO
Help
© 2013-2025 All rights reserved. Tickeron Inc.
+Compare
XBI
ETF ticker: NYSE ARCA
AS OF
Nov 25 closing price
Price
$121.37
Change
+$1.79 (+1.50%)
Net Assets
7.52B

XBI stock forecast, quote, news & analysis

The investment seeks to provide investment results that, before fees and expenses, correspond generally to the total return performance of the S&P Biotechnology Select Industry Index derived from the biotechnology segment of a U... Show more

Category: #Health
XBI
Setup
Setup
Daily Signal:
Description
Gain/Loss:
A.I.Advisor
published price charts
These past five trading days, the ETF lost 0.00% with an average daily volume of 0 shares traded.The ETF tracked a drawdown of 0% for this period.
View AI-Driven Trading for XBI
Interact to see
Advertisement
A.I.Advisor
a Summary for XBI with price predictions
Nov 25, 2025

XBI in +4.05% Uptrend, growing for three consecutive days on November 25, 2025

Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where XBI advanced for three days, in of 305 cases, the price rose further within the following month. The odds of a continued upward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on November 11, 2025. You may want to consider a long position or call options on XBI as a result. In of 93 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for XBI just turned positive on November 21, 2025. Looking at past instances where XBI's MACD turned positive, the stock continued to rise in of 57 cases over the following month. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 223 cases where XBI Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Bearish Trend Analysis

The RSI Indicator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.

The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 9 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where XBI declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

XBI broke above its upper Bollinger Band on November 24, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are ABBVIE (NYSE:ABBV), Amgen (NASDAQ:AMGN), Gilead Sciences (NASDAQ:GILD), Regeneron Pharmaceuticals (NASDAQ:REGN), Biogen (NASDAQ:BIIB), Incyte Corp (NASDAQ:INCY), Exact Sciences Corp (NASDAQ:EXAS), Exelixis (NASDAQ:EXEL), Moderna (NASDAQ:MRNA), Arrowhead Pharmaceuticals (NASDAQ:ARWR).

Industry description

The investment seeks to provide investment results that, before fees and expenses, correspond generally to the total return performance of the S&P Biotechnology Select Industry Index derived from the biotechnology segment of a U.S. total market composite index. In seeking to track the performance of the S&P Biotechnology Select Industry Index (the "index"), the fund employs a sampling strategy. It generally invests substantially all, but at least 80%, of its total assets in the securities comprising the index. The index represents the biotechnology segment of the S&P Total Market Index ("S&P TMI").

Market Cap

The average market capitalization across the State Street® SPDR® S&P® Biotech ETF ETF is 11.88B. The market cap for tickers in the group ranges from 124.08M to 409.68B. ABBV holds the highest valuation in this group at 409.68B. The lowest valued company is SCLX at 124.08M.

High and low price notable news

The average weekly price growth across all stocks in the State Street® SPDR® S&P® Biotech ETF ETF was 5%. For the same ETF, the average monthly price growth was 12%, and the average quarterly price growth was 51%. EXAS experienced the highest price growth at 45%, while AGIO experienced the biggest fall at -38%.

Volume

The average weekly volume growth across all stocks in the State Street® SPDR® S&P® Biotech ETF ETF was -12%. For the same stocks of the ETF, the average monthly volume growth was 5% and the average quarterly volume growth was -8%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 62
P/E Growth Rating: 74
Price Growth Rating: 47
SMR Rating: 84
Profit Risk Rating: 78
Seasonality Score: 20 (-100 ... +100)
View a ticker or compare two or three
GO
VS
Compare
VS
Compare
XBI
Setup
Setup
Daily Signal:
Description
Gain/Loss:
Interact to see
Advertisement
A.I. Advisor
published General Information

General Information

Category Health

Profile
Fundamentals
Details
Category
Health
Address
SPDR Series TrustOne Lincoln Street Cph0326Boston
Phone
N/A
Web
www.spdrs.com